Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-353501      Publish Date : Saturday, October 14, 2017 Visit : 1677

Intl. Congress form | International Congress Report | International Congress Report For Faculty | CRS annual meeting and exposition by Dr. Farid Dorkoosh

CRS annual meeting and exposition by Dr. Farid Dorkoosh
CRS annual meeting and exposition by Dr. Farid Dorkoosh
Farid Dorkoosh | International Congress Form

Application Code :
762-0217-0041
 
Created Date : Tuesday, August 15, 2017-10:03 10:03:35Update Date : Wednesday, September 27, 2017-11:59 11:59:51
IP Address : 172.16.6.23Submit Date : Wednesday, September 27, 2017-11:59 11:59:59Email : dorkoosh@tums.ac.ir
Personal Information
Name : Farid
Surname : Dorkoosh
School/Research center : School of Pharmacy
If you choose other, please name your Research center :  
Position : Associate professor
Tel : +98-21-88009440
Information of Congress
Title of the Congress : CRS annual meeting and exposition
Title of your Abstract : Preparation, characterization and In Vivo evaluation of a combination delivery system based on hyaluronic acid/jeffamine hydrogel loaded with PHBV/PLGA blend nanoparticles for prolonged delivery of Teriparatide
Destination Country : United States
From : Sunday, July 16, 2017
To : Wednesday, July 19, 2017
Abstract(Please copy/paste the abstract send to the congress) : Learning Objectives
1. Develop novel CDS for prolonged delivery of Teriparatide with the aim of reducing the frequency of injection.
2. Design a CDS with more desirable release profile in comparison to NPs and hydrogel alone.
3. Formulate an effective Teriparatide delivery system and preserve the biological bioactivity.

Introduction: Osteoporosis is identified as the most common cause of bone loss particularly in the elderly. Among the different therapeutic options, Teriparatide is the only therapeutic agent which stimulates bone formation. There are only few studies available on Teriparatide sustained release formulation. In the current study, biodegradable PHBV/PLGA blend nanoparticles (NPs) containing Teriparatide were loaded in hyaluronic acid/jeffamine (HA-JEF ED-600) hydrogel to prepare a combination delivery system (CDS) for prolonged delivery of Teriparatide.

Methods: The CDS was prepared by adding Teriparatide loaded PHBV/PLGA NPs to HA-JEF ED-600 hydrogel simultaneously to crosslinking reaction. Swelling behaviour, crosslinking efficiency and rheological characterization of HA-JEF ED-600 hydrogel were evaluated. The percentage of NPs incorporation within the hydrogel, loading capacity and morphology of Teriparatide loaded CDS were examined. The release profile of Teriparatide from CDS was investigated and compared with PHBV/PLGA NPs and HA-JEF ED-600 hydrogel. Teriparatide stability was examined by intrinsic fluorescence and circular dichroism spectroscopy. Cell toxicity was evaluated by MTT assay. LD50 was determined according to Miller and Tainter method. In vivo performance of CDS containing Teriparatide was evaluated by determining serum calcium level in mice.

Results: The CDS showed crosslinking efficacy of 89.9% with a swelling ratio of 178.0%. The rheological studies demonstrated that the viscoelasticity properties shifted from viscous material in HA gel to elastic material in hydrogel. The percentage of NPs incorporation within the hydrogel was figured out to be 86% with 2.31% loading capacity. Intrinsic fluorescence and circular dichroism spectroscopy have proved that Teriparatide is stable after processing. The release profile represented 63% Teriparatide release from CDS within 50 days with lower burst release compared to NPs and hydrogel. MTT assay disclosed no sign of reduction in cell viability. LD50 of Teriparatide loaded CDS was 131.8 mg/kg. In vivo studies demonstrated that Teriparatide loaded CDS could effectively increase serum calcium level after administration in mice.

Conclusion: Favourable results in the current study introduced CDS as a promising candidate for controlled delivery of Teriparatide and pave the way for future investigations in the field of designing prolonged delivery systems for other peptides and proteins.
 
Keywords of your Abstract : hyaluronic acid, jeffamine, hydrogel, PHBV, PLGA , nanoparticles,Teriparatide
 
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/11270/Forms/762/Acceptance_letter_of_Abstract.pdf
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/11270/Forms/762/Front_page_of_Conference_book.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/11270/Forms/762/CRS_Abstract_2017-Nika.pdf
Where has your abstract been indexed? : other
If you choose other, please name : Controlled Release Society Website
The Congress Reporting Form
How many volunteers were present at the Congress? : 1000
Delegates from which countries presented in the congress? : The Netherlands, Switzerlands, Germany, France, Spain, USA, Egypt, Turkey, Iran, UK, Italy, Sweden, Denmark, etc.
Were the delegates of any other organizations present in the congress? : No
If yes, please write the names of the organizations in the box : Not applicable
What were the responses to your talking points? Were specific questions or concerns raised? : There were couple of questions from audiances to our poster.
If you met staff members, please list their full names & positions. : Claus-Michael Lehr
Wim Hennink,
Kinam Park
Vladimir Torchilin
Please inform us if there are any follow up actions we need to talk with the members of the congress :  
Your experiences about the travel processes(Providing ticket, accommodation,...) : As I follow this conference annually for the past 17 years, I have managed it easily in the respect of the whole travel process including ticketing and accommodation.
Please give a briefing of your own observations and outcomes of the congress: : The conference of this year was quite interesting which covered various topics in the field of drug delivery including biological active excipients and carriers, intracellular drug delivery, lipid based drug delivery, new polymers in drug delivery, cell therapies, nutraceuticals, natural structures as drug carriers, ocular delivery, life cycle management of products, encapsulation techniques, co-delivery of various medicines